Advances in targeted drug therapy for acute myeloid leukemia

doi:10.3760/cma.j.issn.1007-1245.2023.08.003

Abstract

Abstract:

Acute myeloid leukemia (AML) is a malignant clonal disease of myeloid cells. In recent years, the emergence of new targeted drugs has revolutionized cancer treatment and is expected to make a breakthrough in the treatment of AML. These new drugs include second-generation DNA methyltransferase inhibitors, B cell lymphoma factor 2 (BCL-2) inhibitors, FMS-like tyrosine kinase 3 (FLT3) inhibitors, isocitrate dehydrogenase inhibitors, anti-CD33 monoclonal antibodies, smoothened inhibitors (SMO), tumor protein p53 targeting drugs, anti-CD47 monoclonal antibodies, and exportin 1 (XPO1) inhibitors. This article reviews the latest targeted therapies for AML.

Key words:

Acute myeloid leukemia, Targeted drugs, Treatment, Progress

摘要：

急性髓系白血病（AML）是一种髓系细胞恶性克隆性疾病。近年来，新型靶向药物的出现使癌症治疗发生了革命性变化，有望在AML治疗上取得突破性进展。这些新药包括二代DNA甲基转移酶抑制剂、靶向B细胞淋巴瘤因子2（BCL-2）抑制剂、FMS样酪氨酸激酶3（FLT3）抑制剂、异柠檬酸脱氢酶抑制剂、抗CD33单克隆抗体、Smoothened Inhibitor（SMO）抑制剂、肿瘤蛋白p53靶向药物、抗CD47单抗、核输出蛋白1（XPO1）抑制剂等。本文就AML最新靶向治疗药物作一综述。

关键词:

急性髓系白血病, 靶向药物, 治疗, 进展

Wang Zechuan, Huang Yueqin.

Advances in targeted drug therapy for acute myeloid leukemia [J]. International Medicine and Health Guidance News, 2023, 29(8): 1045-1048.

王泽川黄月琴.

急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.

References

[1] Döhner H,Wei AH,Appelbaum FR,et al.Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J].Blood,2022,140(12):1345-1377.DOI:10.1182/blood.2022016867.
[2] Nanah R,McCullough K,Hogan W,et al.Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience[J].Am J Hematol,2017,92(9):866-871.DOI:10.1002/ajh.24780.
[3] Döhner H,Wei AH,Roboz GJ,et al.Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine[J].Blood,2022,140(15):1674-1685.DOI:10.1182/blood.2022016293.
[4] Bohl SR,Bullinger L, Rücker FG.Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia[J].Expert Rev Hematol,2018,11(5):361-371.DOI:10.1080/17474086.2018.1453802.
[5] Sébert M,Renneville A,Bally C,et al.A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure[J].Haematologica,2019,104(8):1565-1571.DOI:10.3324/haematol.2018.207118.
[6] Mihalyova J,Jelinek T,Growkova K,et al.Venetoclax: A new wave in hematooncology[J].Exp Hematol,2018,61:10-25.DOI:10.1016/j.exphem.2018.02.002.
[7] Samra B,Konopleva M,Isidori A,et al.Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions[J].Front Oncol,2020,10:562558.DOI:10.3389/fonc.2020.562558.
[8] DiNardo CD,Jonas BA,Pullarkat V,et al.Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J].N Engl J Med,2020,383(7):617-629.DOI:10.1056/NEJMoa2012971.
[9] Lachowiez CA,Reville PK,Kantarjian H,et al.Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study[J].Lancet Haematol,2022,9(5):e350-e360.DOI:10.1016/S2352-3026(22)00076-X.
[10] DiNardo CD,Tiong IS,Quaglieri A,et al.Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML[J].Blood,2020,135(11):791-803.DOI:10.1182/blood. 2019003988.
[11] Röllig C,Serve H,Noppeney R,et al.Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial[J].Leukemia,2021,35(9):2517-2525.DOI:10.1038/s41375-021-01148-x.
[12] Perl AE.The most novel of the novel agents for acute myeloid leukemia[J].Curr Opin Hematol,2018,25(2):81-89.DOI:10.1097/MOH.0000000000000411.
[13] Perl AE,Altman JK,Cortes J,et al.Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study[J].Lancet Oncol,2017,18(8):1061-1075.DOI:10.1016/S1470-2045(17)30416-3.
[14] Perl AE,Larson RA,Podoltsev NA,et al.Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial[J].Blood,2022,139(23):3366-3375.DOI:10.1182/blood. 2021011583.
[15] Ley TJ,Miller C,Ding L,et al.Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J].N Engl J Med,2013,368(22):2059-2074.DOI:10.1056/NEJMoa1301689.
[16] DiNardo CD,Stein EM,de Botton S,et al.Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML[J].N Engl J Med,2018, 378(25):2386-2398.
[17] DiNardo CD,Stein EM,de Botton S,et al.Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML[J].N Engl J Med,2018,378(25):2386-2398.DOI:10.1056/NEJMoa1716984.
[18] Stein EM,DiNardo CD,Pollyea DA,et al.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J].Blood,2017,130(6):722-731.DOI:10.1182/blood-2017-04-779405.
[19] DiNardo CD,Schuh AC,Stein EM,et al.Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial[J].Lancet Oncol,2021,22(11):1597-1608.DOI:10.1016/S1470-2045(21)00494-0.
[20] Sylvie Castaigne.Why is it so difficult to use gemtuzumab ozogamicin?[J].Blood,2013,121(24):4813-4814.DOI:10.1182/blood-2013-05-498683.
[21] Hills RK,Castaigne S,Appelbaum FR,et al.Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials[J].Lancet Oncol,2014,15(9):986-996.DOI:10.1016/S1470-2045(14)70281-5.
[22] Stein EM,Walter RB,Erba HP,et al.A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia[J].Blood,2018,131(4):387-396.DOI:10.1182/blood-2017-06-789800.
[23] Fathi AT,Erba HP,Lancet JE,et al.A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML[J].Blood,2018,132(11):1125-1133.DOI:10.1182/blood-2018- 03-841171.
[24] Finn,Laura S,Moshe Yair Levy,et al.A phase 2 study of actinium-225 (225Ac)-lintuzumab in older patients with previously untreated acute myeloid leukemia (AML) unfit for intensive chemotherapy[J].Blood,2017,130:2638-2638.
[25] Cortes JE,Gutzmer R,Kieran MW,et al.Hedgehog signaling inhibitors in solid and hematological cancers[J].Cancer Treat Rev,2019,76:41-50.DOI:10.1016/j.ctrv.2019.04.005.
[26] Cortes JE,Heidel FH,Hellmann A,et al.Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome[J].Leukemia,2019,33(2):379-389.DOI:10.1038/s41375-018-0312-9.
[27] Liu T,Krysiak K,Shirai CL,et al.Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells[J].PLoS One,2017,12(2):e0170470.DOI:10.1371/journal.pone.0170470.
[28] Lambert JM,Gorzov P,Veprintsev DB,et al.PRIMA-1 reactivates mutant p53 by covalent binding to the core domain[J].Cancer Cell,2009,15(5):376-388.DOI:10.1016/j.ccr.2009.03.003.
[29] Sallman DA,DeZern AE,Garcia-Manero G,et al.Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes[J].J Clin Oncol,2021,39(14):1584-1594.DOI:10.1200/JCO.20.02341.
[30] Chao MP,Takimoto CH,Feng DD,et al.Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies[J].Front Oncol,2020,9:1380.DOI:10.3389/fonc.2019.01380.
[31] Liu J,Wang L,Zhao F,et al.Pre-Clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential[J].PLoS One,2015,10(9):e0137345.DOI:10.1371/journal.pone.0137345.
[32] Sallman DA,Asch AS,Kambhampati S,et al.The first- in-class anti- CD47 antibody magrolimab combined with azacitidine is well- tolerated and effective in AML patients: phase 1b results[J].ASH Annual Meeting Abstract,2020:330.
[33] Nachmias B,Schimmer AD.Targeting nuclear import and export in hematological malignancies[J].Leukemia,2020,34(11):2875-2886.DOI:10.1038/s41375-020-0958-y.
[34] Garzon R,Savona M,Baz R,et al.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia[J].Blood,2017,129(24):3165-3174.DOI:10.1182/blood-2016- 11-750158.
[35] Janssen JJWM,Löwenberg B,Manz M,et al.Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome[J].Leukemia,2022,36(9):2189-2195.DOI:10.1038/s41375-022-01657-3.